couter

AMWLAmerican Well Corporation

American Well Corporation (AMWL) sells telehealth and digital health services, including virtual care platforms and mental health solutions. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to stabilize revenue and narrow its net loss after a year of declining top-line growth.

  • AMWL’s business is built on scaling digital health services, but its recent financials show a struggle to turn revenue into profit.
  • The company faces a critical test in Q3 2026, with earnings and guidance likely to shape investor sentiment.
  • A recent study highlighted the effectiveness of Amwell’s mental health platform, but that doesn’t translate to immediate financial upside.
Nov 5, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Thu5Nov

    The earnings release will test the company's ability to deliver revenue growth and margin expansion, particularly in the telehealth segment, following a recent drop in guidance. This differs from the last print where the focus was on cash burn and operational efficiency.

  • Sun31Jan

    Scheduled commercial rollout of AMWL's new generative AI scribe tools and enhanced virtual workflow integrations aimed at reducing provider burnout and increasing Converge platform utilization.

  • Fri5Feb

    This release will focus on the company's ability to sustain revenue growth and improve cash flow, particularly in the context of a potential regulatory shift in the telehealth space. The last similar print saw a focus on cost control and operational efficiency.

  • Fri12Feb

    The FY 2026 results and strategic capital plan will test the company's ability to execute its long-term strategy, particularly in terms of capital allocation and investment in growth initiatives.

  • Tue4May

    The earnings release will test the company's ability to deliver consistent revenue growth and improve profitability, particularly in the context of a potential shift in healthcare policy. This differs from the last print where the focus was on cost control and operational efficiency.

  • Wed4Aug

    This release will test the company's ability to deliver consistent revenue growth and improve profitability, particularly in the context of a potential shift in healthcare policy. The last similar print saw a focus on cost control and operational efficiency.

  • Thu4Nov

Past

  • Wed5Aug

    Actual outcome: Bull · $11.49 at outcome

    AMWL beat EPS estimates of -$0.60 by -$0.06, narrowing its adjusted EBITDA loss and raising full-year profitability guidance to achieve operating and cash-flow breakeven by Q4. The stock surged on news of the DHA's intent to make Amwell a prime contractor, signaling strong validation of its platform and boosting confidence in its long-term growth prospects despite revenue declines.

    AMWL will report Q2 results with investors highly focused on the company's ability to maintain its dramatically improved cash burn trajectory (net loss improved to -$10.8M last quarter) against shrinking top-line revenues.

  • Wed15Jul

    Actual outcome: Bull · $10.75 at outcome

    American Well shares surged ahead of the CMS 2027 Physician Fee Schedule Proposed Rule, soaring 11.1% on heavy trading volume just prior to the event. This strong momentum drove the stock well above the $9.50 bull target to close at $10.95, reflecting market optimism around telehealth reimbursement rates despite cautious near-term earnings estimate revisions.

    The Centers for Medicare & Medicaid Services (CMS) is expected to release the proposed 2027 Physician Fee Schedule, detailing telehealth reimbursement rates and regulatory extensions under the Trump administration.

  • Tue5May

    Actual outcome: Bull · $8.48 at outcome

    Amwell reported Q1 2026 results that met EPS expectations and topped revenue estimates, signaling potential stabilization amid its Converge platform transition. The better-than-expected top-line performance and subsequent analyst upgrades sparked strong momentum, driving the stock up over 33% to easily exceed the bull target.

    AMWL reports Q1 results with a focus on whether the -22.1% YoY revenue contraction is finally bottoming out as clients migrate to the Converge platform.